Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

GSK and Pfizer merge consumer branches

GlaxoSmithKline (GSK) and Pfizer have merged the parts of their companies selling retail and over-the-counter products into one business.

Following the completion of the merger of the consumer arms of GSK and Pfizer on August 1, the two companies have established the single business under the name of GSK Consumer Healthcare.

The new venture combines each manufacturer’s brands into one portfolio that includes Sensodyne, Voltarol, Panadol, Corsodyl, Anadin, Centrum and Nexium.

GSK Consumer Healthcare is “the world’s number one over-the-counter business”, GSK said.

Jon Workman, who leads GSK Consumer Healthcare, said: “We are embarking on a long-term self-care movement with the aim of sustaining a shift in the behaviours of the nation – getting people to think ‘pharmacist first’ and avoid unnecessary visits to the GP and A&E in the longer term.”

What do you make of this new business?

Related Content

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD006672

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel